Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Special Meeting scheduled for June 18, 2026, to vote on a reverse stock split and potential adjournment if more time is needed for proxy solicitation.
The reverse stock split aims to increase the share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.
The Board has discretion to set the split ratio between 1-for-2 and 1-for-20 at any time within one year of the meeting.
If delisted from Nasdaq, shares may trade OTC, which carries higher risks and reduced liquidity.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20, at the Board's discretion.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.
Both proposals require a majority of shares present or represented by proxy to pass.
No other proposals will be presented at the meeting.
Board of directors and corporate governance
The Board has full discretion to determine if and when to implement the reverse split within one year of approval.
Board members and executive officers are listed with their beneficial ownership in the proxy.
The Board may abandon the reverse split if it is no longer deemed in the best interests of the company.
Latest events from Beyond Air
- Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 202613 Apr 2026 - Patented tankless NO technology drives rapid growth and pipeline expansion in respiratory and oncology markets.XAIR
Corporate presentation23 Mar 2026 - Revenue grew to $1.2M, guidance lowered, and regulatory delays impacted margins.XAIR
Q4 20243 Feb 2026 - Offering up to 7.86M shares for resale, with proceeds from warrant exercises for corporate use.XAIR
Registration Filing30 Jan 2026 - Second-generation nitric oxide device targets major U.S. and global market share growth.XAIR
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - LungFit PH revolutionizes NO therapy with on-demand generation, global reach, and expanding clinical pipeline.XAIR
Corporate presentation15 Jan 2026 - Hospital client base grew 60% and revenue quadrupled, with losses narrowed and cash runway extended.XAIR
Q2 202515 Jan 2026 - CE Mark approval, new partnerships, and next-gen product set stage for global growth in 2025-27.XAIR
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Innovative nitric oxide system drives growth, global expansion, and pipeline progress.XAIR
Lytham Partners 2025 Investor Healthcare Summit10 Jan 2026